VERA
Vera Therapeutics, Inc
ACTIONABLEMethodology gates passed
Position levels
Currenttoday
USD 32.89
Buy <=wait / entry
USD 22.00
Trim >=take some off
USD 30.00
Thesis breakA material clinical or regulatory setback for atacicept in IgAN, or a dilutive e...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 20% | 100 / 100 | 20.0 |
| Base case | 50% | 62 / 100 | 31.0 |
| Bear case | 30% | 10 / 100 | 3.0 |
| Weighted conviction | 54 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- Q1 2026 EPS miss of $0.36 versus consensus
- Projected EPS improvement from ($6.37) to ($3.94) next year
- Analyst consensus 89% buy or strong buy ratings